Abstracts tagged "modifiable risk"

Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 1141 • 2018 ACR/ARHP Annual Meeting
Trajectories of Extensive Sitting and Associated Predictors in Persons at High Risk for Knee Osteoarthritis
Julia (Jungwha) Lee¹, Alison H. Chang², Orit Almagor², Joan S. Chmiel³, Karen W. Hayes², C. Kent Kwoh⁴ and Leena Sharma⁵, ¹Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Too much sitting has been recognized as a major public health issue. However, it is unknown if distinctive patterns of extensive sitting over time…
Abstract Number: 2134 • 2018 ACR/ARHP Annual Meeting
Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
Amelia Green^1,2, Gavin Shaddick³, Rachel Charlton¹, Julia Snowball¹, Alison L Nightingale¹, Catherine Smith⁴, William Tillet^1,5 and Neil McHugh^1,5, ¹Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ²Department of Mathematical Sciences, The University of Bath, Bath, United Kingdom, ³Centre for Data Science and Statistics, The University of Exeter, Bath, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, St John’s Institute of Dermatology, London, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired…
Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Pomme Poppelaars¹, Lilian van Tuyl² and Maarten Boers^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands
ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 1410 • 2014 ACR/ARHP Annual Meeting
Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Kimberly P. Liang¹, Rohit Aggarwal², Juan (June) Feng³, Jason Lyons³, Heather Eng³, Stephen R. Wisniewski³, Melissa Saul⁴, Douglas P. Landsittel⁵, Douglas W. Chew¹, Aryan Aiyer⁶ and Larry W. Moreland⁷, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite higher risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA), systematic cardiovascular (CV) prevention strategies are lacking. Recent guidelines for CV risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].